Targeted Strategies for Today's Evolving Markets

MissionIR Blog

IRIDEX Corporation (IRIX) Receives FDA 510(k) Clearance for IQ Laser Systems

IRIDEX Corporation (NASDAQ: IRIX), a worldwide leader in the development, manufacturing, and marketing innovative and versatile light-based medical systems and delivery devices, recently announced receipt of FDA 510(k) clearance for its suite of IRIDEX IQ Laser Systems, covering the IRIDEX IQ 532, IQ 577, IQ 630-670 and IQ 810 Laser Systems along with their associated delivery devices. The company developed these laser systems to assist with a wide range of specific applications in the medical specialties of ophthalmology, ear, nose and throat (ENT)/otolaryngology and dermatology.

The company’s president and chief operating officer, Mr. Theodore A. Boutacoff, recently stated, “We are pleased to have passed this regulatory milestone. The design concept of the IQ Family enables us to provide different solid-state lasers on a common platform. The first product to be released to market using this platform will be the IQ 577™, which provides a wavelength and technology that complements our product portfolio and is not commercially available from any of our competitors.”

Founded in 1989, IRIDEX Corporation is an innovative provider of therapeutic based laser systems, disposable laser probes and delivery devices to treat eye diseases in ophthalmology and skin disorders in the global aesthetics market. IRIDEX products are sold in the United States and internationally through direct sales teams and a network of approximately 100 independent distributors in more than 100 countries worldwide.

Let us hear your thoughts below:

This entry was posted in Small Cap News. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *